Omidubicel-Onlv: The First Commercially Available Alternative Allogeneic Hematopoietic Stem Cell Transplantation Donor Source.
BACKGROUND: Although allogeneic hematopoietic stem cell transplantation (alloHSCT) can be a lifesaving therapy for patients with hematologic malignancies, only 30% of patients in need of transplantation will have a human leukocyte antigen matched related donor available. OBJECTIVES: This article int...
| Publicado en: | Clinical Journal of Oncology Nursing Vol. 29; no. 3; pp. 230 - 237 |
|---|---|
| Autores principales: | , |
| Formato: | glossary tables/charts Journal Article |
| Publicado: |
Oncology Nursing Society
Jun2025
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=185395789&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 185395789 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 10921095 GNN jtl: Clinical Journal of Oncology Nursing issn: 10921095 maglogo: N pubinfo: dt: Jun2025 vid: 29 iid: 3 pid: 12496 pub: Oncology Nursing Society place: Pittsburgh, Pennsylvania artinfo: ui: 185395789 185395789 185395789 10.1188/25.CJON.230-236 185395789 ppf: 230 ppct: 7 formats: fmt: @attributes: type: P tig: atl: Omidubicel-Onlv: The First Commercially Available Alternative Allogeneic Hematopoietic Stem Cell Transplantation Donor Source. aug: au: Lassiter, Martha Lail, Charlotte affil: Search optimization specialist at Gamida Cell in Boston, MA sug: subj: Hematologic Neoplasms Therapy Hematopoietic Stem Cell Transplantation Nursing Allogeneic Cells Transplantation Cell Therapy Methods Fetal Blood Cells, Cultured Transplantation Nursing Care Hematologic Neoplasms Physiopathology Transplant Donors Allografts Hematopoietic Stem Cells Cell Culture Techniques Drug Development Information Resources ab: BACKGROUND: Although allogeneic hematopoietic stem cell transplantation (alloHSCT) can be a lifesaving therapy for patients with hematologic malignancies, only 30% of patients in need of transplantation will have a human leukocyte antigen matched related donor available. OBJECTIVES: This article introduces an approved alternative donor stem cell source that is shown to provide earlier engraftment and decreased infections compared to dual or single umbilical cord blood transplantation. METHODS: This article provides an overview of the pathophysiology, clinical trial results, and nursing management of the approved omidubicel-onlv cellular therapy product as an alternative donor source for patients undergoing alloHSCT. FINDINGS: Omidubicel provides an alternative donor source for patients undergoing alloHSCT for whom there is no matched donor available. This need may be particularly great in ethnic and racial minority populations who may be underrepresented in the NMDP BioTherapies database. pubtype: Academic Journal doctype: glossary tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|